ChiehYing Chang
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Chronic Lymphocytic Leukemia Research, Alzheimer's disease research and treatments
Most-Cited Works
- → Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers(2016)144 cited
- → Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development(2009)94 cited
- → Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)(2016)51 cited
- → Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases(2014)39 cited
- → Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists(2008)37 cited
- → Design, synthesis and structure–activity relationships of azole acids as novel, potent dual PPAR α/γ agonists(2009)35 cited
- → Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)(2015)28 cited
- → The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor(2014)26 cited
- → De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold(2005)23 cited
- → Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase(2010)22 cited